Medexus Pharmaceuticals Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Medexus Pharmaceuticals de 52.7% y 14.2% por año respectivamente. Se prevé que el BPA crezca en un 52.7% al año. Se espera que la rentabilidad financiera sea de 32% en 3 años.
Información clave
52.7%
Tasa de crecimiento de los beneficios
52.68%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 12.4% |
| Tasa de crecimiento de los ingresos | 14.2% |
| Rentabilidad financiera futura | 32.00% |
| Cobertura de analistas | Low |
| Última actualización | 29 Jun 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Jun 17
MDP: Share Repurchases And New Cell Therapy Rights Will Support Upside
Analysts have modestly adjusted their fair value price target for Medexus Pharmaceuticals stock to CA$8.00, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations, while keeping the overall valuation level unchanged. What's in the News for Medexus Pharmaceuticals Secured exclusive Canadian rights to commercialize UM171 Cell Therapy, branded as Zemcelpro (dorocubicel) in Europe, through a license and supply agreement with ExCellThera and its subsidiary Cordex Biologics.Actualización de narrativa • Jun 02
MDP: Ongoing Share Repurchases Will Support Upside Potential
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E as the key drivers of the revised valuation. What's in the News Medexus reported an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, with 56 healthcare institutions having granted positive formulary inclusion decisions as of March 31, 2026, and 64 transplant centers having ordered the product for procedures.Actualización de narrativa • Apr 27
MDP: Share Repurchases And Transplant Center Adoption Will Support Upside
Analysts have modestly raised their CA$ price target on Medexus Pharmaceuticals, citing slightly higher modeled revenue growth of 21.21% and a profit margin assumption of 24.84%, while keeping the fair value and discount rate unchanged. What's in the News Medexus provided an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, including recent progress with transplant center formulary decisions and ordering activity.Actualización de narrativa • Apr 09
MDP: Share Buyback And Higher Future P E Multiple Will Support Upside
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth, profit margins, and future P/E that refine their outlook on the company’s valuation. What's in the News Medexus Pharmaceuticals completed a share buyback tranche covering 191,900 shares, equal to 0.59% of its shares, between November 20, 2025 and December 31, 2025 (Key Developments).Actualización de narrativa • Mar 26
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have modestly lifted their price target on Medexus Pharmaceuticals to CA$8.00, reflecting slightly higher modeled revenue growth, a small uptick in profit margin assumptions, and a marginally lower future P/E multiple. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares from November 20, 2025 to December 31, 2025, representing 0.59% of its shares, for a total of CA$0.52 million under its previously announced buyback program (Key Developments).Actualización de narrativa • Mar 11
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have raised their CA$ price target on Medexus Pharmaceuticals, citing slightly stronger modeled revenue growth of 19.57% and a profit margin of 27.71%, along with a modestly lower forward P/E of 4.80x in their updated assumptions. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of shares, for CAD 0.52 million under its buyback program announced on November 20, 2025 (Key Developments).Actualización de narrativa • Feb 25
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have revised their CA$ price target on Medexus Pharmaceuticals upward, reflecting updated assumptions that include modeled revenue growth of 19.35%, a profit margin of 27.36% and a slightly lower forward P/E of 4.85x. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of its outstanding equity, for a total cost of CA$0.52 million under the buyback announced on November 20, 2025 (Key Developments).Actualización de narrativa • Feb 10
MDP: Share Repurchase Plan Will Support Higher Future Shareholder Value
Analysts have modestly adjusted their price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth of about 17.94%, profit margin of about 25.99% and a future P/E of about 5.10x. Together, these figures inform a refreshed fair value view of US$8.00 per share.Actualización de narrativa • Jan 26
MDP: Share Repurchase Plan Will Support Stronger Future Shareholder Returns
Analysts have lifted their price target on Medexus Pharmaceuticals to US$8.00 from US$8.00, citing slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a small adjustment to the future P/E assumption. What's in the News Medexus Pharmaceuticals has announced a share repurchase program that allows the company to buy back up to 2,983,650 shares, or 9.2% of its issued share capital, with all repurchased shares set to be cancelled.Actualización de narrativa • Jan 11
MDP: Share Repurchase Program Will Support Stronger Future Shareholder Returns
Analysts have reaffirmed their price target on Medexus Pharmaceuticals at US$8.00, citing updated assumptions for revenue growth, profit margins, and future P/E that adjust their overall outlook while keeping the fair value level unchanged. What's in the News Medexus Pharmaceuticals Inc.Artículo de análisis • Jan 03
Does Medexus Pharmaceuticals (TSE:MDP) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Actualización de narrativa • Dec 16
MDP: Share Repurchase Program Will Drive Stronger Future Shareholder Returns
Analysts have raised their price target for Medexus Pharmaceuticals to approximately $8.00 per share from about $6.00, citing expectations of stronger revenue growth, a substantial improvement in profit margins, and a lower projected future P/E multiple that enhances the stock's valuation appeal. What's in the News Medexus Pharmaceuticals Inc.
Actualización de narrativa • Aug 20
US Transplant Centers Will Drive Specialty Care Adoption
Despite notable improvements in net profit margin and revenue growth forecasts, the consensus analyst price target for Medexus Pharmaceuticals has been revised downward from CA$7.11 to CA$6.71. What's in the News Medexus Pharmaceuticals received approval from US CMS for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX™ (treosulfan) for Injection for fiscal year 2026.Actualización de narrativa • Aug 06
US Transplant Centers Will Drive Specialty Care Adoption
The notable increase in Medexus Pharmaceuticals' consensus price target is primarily driven by a significant rise in its future P/E valuation, with fair value revised upward from CA$6.50 to CA$7.11. Valuation Changes Summary of Valuation Changes for Medexus Pharmaceuticals The Consensus Analyst Price Target has risen from CA$6.50 to CA$7.11.Artículo de análisis • May 04
Earnings Tell The Story For Medexus Pharmaceuticals Inc. (TSE:MDP) As Its Stock Soars 28%
Those holding Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares would be relieved that the share price has rebounded 28...
Nueva narrativa • Feb 19
FDA Approval Of GRAFAPEX Will Unlock Market Potential With 7 Years Exclusivity
Successful FDA approval for GRAFAPEX is expected to significantly increase revenue, providing a robust new stream with its granted exclusivity.Artículo de análisis • Jan 19
Investors Appear Satisfied With Medexus Pharmaceuticals Inc.'s (TSE:MDP) Prospects As Shares Rocket 52%
Despite an already strong run, Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have been powering on, with a gain of...Artículo de análisis • Dec 05
After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 31% after a shaky period...Artículo de análisis • Nov 05
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Medexus Pharmaceuticals Inc.'s ( TSE:MDP ) stock was strong despite it releasing a soft earnings report last week. We...Artículo de análisis • Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Medexus Pharmaceuticals Inc. ( TSE:MDP ) just released its latest quarterly results and things are looking bullish. It...Artículo de análisis • Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shareholders have had their patience rewarded with a 29% share price jump in...Artículo de análisis • Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Artículo de análisis • Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
The Medexus Pharmaceuticals Inc. ( TSE:MDP ) share price has softened a substantial 26% over the previous 30 days...Artículo de análisis • Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 89% after a shaky period...Artículo de análisis • Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2029 | 161 | 42 | N/A | 44 | 4 |
| 3/31/2028 | 139 | 24 | N/A | 30 | 5 |
| 3/31/2027 | 113 | 9 | N/A | 17 | 5 |
| 3/31/2026 | 99 | -2 | 4 | 19 | N/A |
| 12/31/2025 | 99 | 0 | 10 | 17 | N/A |
| 9/30/2025 | 104 | 0 | 13 | 16 | N/A |
| 6/30/2025 | 106 | 1 | 14 | 20 | N/A |
| 3/31/2025 | 108 | 2 | 21 | 24 | N/A |
| 12/31/2024 | 110 | 4 | 20 | 23 | N/A |
| 9/30/2024 | 105 | 2 | 19 | 22 | N/A |
| 6/30/2024 | 109 | 1 | 22 | 23 | N/A |
| 3/31/2024 | 113 | 0 | 18 | 19 | N/A |
| 12/31/2023 | 116 | 6 | 21 | 21 | N/A |
| 9/30/2023 | 119 | 5 | 13 | 13 | N/A |
| 6/30/2023 | 117 | 3 | 6 | 7 | N/A |
| 3/31/2023 | 108 | 1 | -2 | -1 | N/A |
| 12/31/2022 | 100 | -11 | -3 | -2 | N/A |
| 9/30/2022 | 92 | -11 | -3 | -1 | N/A |
| 6/30/2022 | 82 | 2 | 0 | 2 | N/A |
| 3/31/2022 | 77 | -3 | -9 | -1 | N/A |
| 12/31/2021 | 74 | -8 | -17 | -1 | N/A |
| 9/30/2021 | 77 | -20 | -18 | -1 | N/A |
| 6/30/2021 | 77 | -31 | -21 | -5 | N/A |
| 3/31/2021 | 80 | -28 | -6 | 5 | N/A |
| 12/31/2020 | 79 | -19 | -1 | 0 | N/A |
| 9/30/2020 | 69 | -9 | 1 | 1 | N/A |
| 6/30/2020 | 64 | -7 | 1 | 1 | N/A |
| 3/31/2020 | 56 | -5 | -3 | -2 | N/A |
| 12/31/2019 | 47 | -4 | N/A | 0 | N/A |
| 9/30/2019 | 45 | -3 | N/A | 0 | N/A |
| 6/30/2019 | 36 | -6 | N/A | -1 | N/A |
| 3/31/2019 | 25 | -5 | N/A | -1 | N/A |
| 12/31/2018 | 17 | -5 | N/A | -2 | N/A |
| 9/30/2018 | 9 | -5 | N/A | -1 | N/A |
| 6/30/2018 | 8 | -2 | N/A | -2 | N/A |
| 3/31/2018 | 8 | -3 | N/A | -3 | N/A |
| 12/31/2017 | 8 | -3 | N/A | -3 | N/A |
| 9/30/2017 | 7 | -3 | N/A | -4 | N/A |
| 6/30/2017 | 6 | -3 | N/A | -4 | N/A |
| 3/31/2017 | 5 | -1 | N/A | -1 | N/A |
| 12/31/2016 | 4 | 1 | N/A | 1 | N/A |
| 9/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 6/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 3/31/2016 | 3 | -2 | N/A | -1 | N/A |
| 12/31/2015 | 3 | -4 | N/A | -3 | N/A |
| 9/30/2015 | 2 | -4 | N/A | -3 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que MDP sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3%).
Beneficios vs. Mercado: Se prevé que MDP sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que MDP sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (14.2% al año) de MDP crezcan más rápidamente que los del mercado Canadian (4.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 14.2% al año) de MDP crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de MDP sea alta dentro de 3 años (32%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/28 21:54 |
| Precio de las acciones al final del día | 2026/07/28 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Medexus Pharmaceuticals Inc. está cubierta por 10 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Scott Henry | Alliance Global Partners |
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |